SyneuRx International (Taiwan) Corp.

SyneuRx International (Taiwan) Corp. is a biopharmaceutical company headquartered in Taiwan, with a focus on developing new classes of drugs for COVID-19 and multiple major central nervous system disorders. Their slogan, "Developing new classes of drugs for COVID-19 and multiple major central nervous system disorders," reflects their mission to address significant unmet needs in healthcare. The company has made significant progress in the development of antiviral drugs for COVID-19. Their clinical programs include Pentarlandir® as an oral capsule and Airnecflu® as an inhaled treatment. SyneuRx's research on regulatory enzymes such as protease has led to the discovery of Pentarlandir, which demonstrated efficacy in blocking coronavirus replication while maintaining an excellent safety profile. Their efforts have attracted an equity investment from Taiwania Capital Management Corporation in August 2022. Additionally, SyneuRx is exploring the modulation of NMDA receptors for treating CNS disorders. They believe that NMDA receptors play a crucial role in regulating brain function and aim to develop therapies that modulate NMDA receptor functions to address unmet needs in CNS disorders. Overall, SyneuRx International (Taiwan) Corp. is dedicated to using a humanistic approach to bring breakthrough therapeutics to diseases and conditions with significant unmet needs in the biopharmaceutical and pharmaceutical industries.